United States: The Past, Present, And Future Of Government Regulation Of Off-Label Communications – Part 2

In my last post, I introduced a series of posts that will explore FDA's historical approach to off-label drug and device communications, how that position has evolved (or not) to the modern day, and predict where that policy might end up a few years from now. This post focuses on the history of FDA's off-label communication and promotion policy, and while it is by no means a comprehensive history, I attempt to reveal some of the origins and early development of the Agency's approach to off-label uses and promotion. In fact, FDA's early position on off-label communications closely resembles the Agency's stance on the subject today.

The Basis of the Off-Label Communications Prohibition: The Statute

As with most issues related to FDA, the basic origins of the Agency's off-label promotion policy trace back to the Food, Drug, and Cosmetic Act ("FDCA"). Although there is no explicit language in the FDCA granting FDA the power to prohibit off-label activities, the primary authority to regulate communications about unapproved uses derives from the following sections of the FDCA as enacted in the U.S. Code:

  • 21 U.S.C. § 331(a) – Prohibiting the introduction of regulated products that are adulterated or misbranded into interstate commerce.
  • 21 U.S.C. § 331(k) – Prohibiting any act with respect to a regulated product after shipment in interstate commerce that results in the product being adulterated or misbranded.
  • 21 U.S.C. § 352(f)(1) – Deeming a drug or device misbranded if the labeling does not bear adequate directions for its intended use.
  • And to a lesser extent, 21 U.S.C. § 352(a) – Deeming a drug or device misbranded if the labeling is false or misleading.

These statutory sections have been in force since the FDCA was first enacted in 1938 and are common references throughout the history of FDA's regulation of off-label communication. Not surprisingly, FDA cites these very sections as the basis for its authority in the memo discussing the Agency's current position on off-label uses and communications.

Early Regulations Related to Off-Label Communications

Much of the analysis for identifying off-label communications rests on a regulated product's intended use. Although many of the permissions and prohibitions described in the FDCA are based on intended use, FDA did not actually seek to define the phrase until 1952, when Title 21 of the CFR was amended with Section 1.106(o) (17 Fed. Reg. 6818, 6820). While the regulation did explain the meaning of intended use, it also added the following warning to industry: "But if a manufacturer knows or has knowledge of facts that would give him notice, that a drug or device introduced into interstate commerce by him is to be used for conditions, purposes, or uses other than the ones for which he offers it, he is required to provide adequate labeling for such a drug which accords with such other uses to which the article is to be put." The language of 21 C.F.R. 1.106(o) should look familiar to anyone today because the same language is codified in 21 C.F.R. §§ 201.128 and 801.4, and in the language FDA attempted to change in a final rule released in January.

FDA built off of this intended use concept in developing proposed regulations governing off-label uses and communications. In 1972, faced with "widespread use of certain prescription drugs for conditions not named in the official labeling," the Agency stated:

Section 1.106 of the regulations requires the labeling to contain appropriate information with respect to all intended uses of the drugs. Thus, where a manufacturer or his representative, or any person in the chain of distribution, does anything that directly or indirectly suggests to the physician or to the patient that an approved drug may properly be used for unapproved uses for which it is neither labeled nor advertised, that action constitutes a direct violation of the [FDCA] and is punishable accordingly. (37 Fed. Reg. 16,503, 16,504)

Based on this reasoning, FDA proposed, in part, the following regulations:

  • 21 C.F.R. § 130.___(a)(2) – "A prescription new drug may not be shipped in interstate commerce when intended for uses not contained in the currently approved labeling. Such unapproved uses may include, inter alia, a different dosage, or a different patient population, or a different regimen, than that approved. Section 505 of the [FDCA] requires that a manufacturer, physician, or other person who ships or requests shipment of a prescription new drug in interstate commerce, with the intent, or for the purpose, of an unapproved use must first file with [FDA] an investigational new drug plan . . . ."
  • 21 C.F.R. § 130.___(a)(3) – "Once a prescription new drug has been shipped in interstate commerce intended for its approved use(s) under approved labeling, the [FDCA] does not require a physician to file with [FDA] an investigational new drug plan in order to lawfully prescribe the drug for an unapproved use, when such prescribing is done as part of the practice of medicine." (37 Fed. Reg. 16,503, 16,504-05)

The remaining sections state that when an off-label use may endanger patients or create a public health hazard, FDA has the authority to revise the labeling, obtain relevant data from the manufacturer, restrict distribution, or revoke the applicable NDA.

In this proposed regulation, FDA also drew a bright line distinction between advertising a drug for off-label uses as part of commercial activities and doctors prescribing or using a drug off-label in their professional judgment. FDA held that this distinction was faithful to the original intent behind the FDCA, stating:

Under the [FDCA], a drug approved for marketing may be labeled, promoted, and advertised by the manufacturer only for those uses for which the drug's safety and effectiveness have been established and which FDA has approved. . . . The [FDCA] does not, however, limit the manner in which a physician may use an approved drug. (FDA Drug Bulletin, April 1982).

An Off-Label Policy Takes Hold

The proposed regulations were never finalized, but FDA continued to refer to them in future publications, stating "although no final rule has been issued on this subject, the agency has continued to apply the principles set forth in the preamble to the 1972 proposal" (48 Fed. Reg. 26,720, 26,733 (1983)). In a proposed rulemaking for a standard drug label format, FDA also cited the 1972 proposed rule and stated: "No clinical studies or references cited in [drug] labeling may refer to indications or uses not stated in the package insert. . . . The Commissioner concludes . . . that it is neither lawful nor in the interest of good patient care for the package insert to contain references to indications or usages for which substantial evidence of safety and effectiveness is not available" (40 Fed. Reg. 15,392, 15,393-94 (1975)).

Federal courts also appeared to support the Agency's regulation of off-label communications according to this policy. In U.S. v. Evers, 643 F.2d 1043 (5th Cir. 1981), the Court of Appeals for the Fifth Circuit cited the 1972 proposed rule and stated that it was the basis of advice FDA gave to a physician about the off-label use of an approved drug. Even before the proposed rule was published, the Court of Appeals for the Ninth Circuit held that a company had misbranded its product by publishing newspaper advertisements stating that the product could treat arthritis and rheumatism when such indications were not described on the product label (Alberty Food Products Co. v. U.S., 185 F.2d 321 (9th Cir. 1950)).

That's all for the moment on the history behind FDA's stance on off-label communications. Next time, I will discuss some prominent FDA Warning Letters, other enforcement actions, and guidance documents relating to off-label promotions.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.